|
1
|
Katsura C, Ogunmwonyi I, Kankam HKN and
Saha S: Breast cancer: Presentation, investigation and management.
Br J Hosp Med (Lond). 83:1–7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Singh H: Role of molecular targeted
therapeutic drugs in treatment of breast cancer: A review article.
Global Med Genet. 10:79–86. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhai J, Wu Y, Ma F, Kaklamani V and Xu B:
Advances in medical treatment of breast cancer in 2022. Cancer
Innov. 2:1–17. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chatterjee A: Long term effects of modern
breast cancer surgery. Gland Surg. 7:366–370. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haque W, Butler EB and Teh BS:
Personalized radiation therapy for breast cancer. Curr Oncol.
31:1588–1599. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bartsch R and Bergen E: SABCS 2017: Update
on chemotherapy, targeted therapy, and immunotherapy. Memo.
11:204–207. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi L, Chen Z and Wang X: ASCO 2018:
Recent advances in endocrine therapy for advanced breast cancer.
Chin J Clin Oncol. 45:919–921. 2018.
|
|
8
|
Bhave MA and Henry NL: Extended endocrine
therapy: Is 5 years enough? Curr Oncol Rep. 19:162017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barroso-Sousa R, Silva DDAFR, Alessi JVM
and Mano MS: Neoadjuvant endocrine therapy in breast cancer:
Current role and future perspectives. Ecancermedicalscience.
10:6092016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jordan VC and O'Malley BW: Selective
estrogen-receptor modulators and antihormonal resistance in breast
cancer. J Clin Oncol. 25:5815–5824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang W, Xu J, Shi Y, Sun Q, Zhang Q and
Guan X: The novel role of miRNAs for tamoxifen resistance in human
breast cancer. Cell Mol Life Sci. 72:2575–2584. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ring A and Dowsett M: Mechanisms of
tamoxifen resistance. Endocr Relat Cancer. 11:643–658. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yao J, Deng K, Huang J, Zeng R and Zuo J:
Progress in the understanding of the mechanism of tamoxifen
resistance in breast cancer. Front Pharmacol. 11:5929122020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang M: Tamoxifen resistance in breast
cancer. Biomol Ther (Seoul). 20:256–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen Y: Recent advances in methylation: A
guide for selecting methylation reagents. Chemistry. 25:3405–3439.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Castillo-Aguilera O, Depreux P, Halby L,
Arimondo PB and Goossens L: DNA methylation targeting: The DNMT/HMT
crosstalk challenge. Biomolecules. 7:32017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jahangiri R, Jamialahmadi K, Gharib M,
Emami Razavi A and Mosaffa F: Expression and clinicopathological
significance of DNA methyltransferase 1, 3A and 3B in
tamoxifen-treated breast cancer patients. Gene. 685:24–31. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jahangiri R, Mosaffa F, Emami Razavi A,
Teimoori-Toolabi L and Jamialahmadi K: Altered DNA
methyltransferases promoter methylation and mRNA expression are
associated with tamoxifen response in breast tumors. J Cell
Physiol. 233:7305–7319. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin X, Li J, Yin G, Zhao Q, Elias D,
Lykkesfeldt AE, Stenvang J, Brünner N, Wang J, Yang H, et al:
Integrative analyses of gene expression and DNA methylation
profiles in breast cancer cell line models of tamoxifen-resistance
indicate a potential role of cells with stem-like properties.
Breast Cancer Res. 15:R1192013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Hong T, Wang S, Mo J, Tian T and
Zhou X: Epigenetic modification of nucleic acids: From basic
studies to medical applications. Chem Soc Rev. 46:2844–2872. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu L, Davis IJ and Liu P: Regulation of
EWSR1-FLI1 function by Post-Transcriptional and Post-Translational
modifications. Cancers (Basel). 15:3822023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zaib S, Rana N and Khan I: Histone
modifications and their role in epigenetics of cancer. Curr Med
Chem. 29:2399–2411. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu WW, Zheng SQ, Li T, Fei YF, Wang C,
Zhang S, Wang F, Jiang GM and Wang H: RNA modifications in cellular
metabolism: Implications for metabolism-targeted therapy and
immunotherapy. Signal Transduct Target Ther. 9:702024. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Song T, Lv S, Li N, Zhao X, Ma X, Yan Y,
Wang W and Sun L: Versatile functions of RNA m6A machinery on
chromatin. J Mol Cell Biol. 14:mjac0112022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Singh V, Ram M, Kumar R, Prasad R, Roy BK
and Singh KK: Phosphorylation: Implications in Cancer. Protein J.
36:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu X, Xu M, Geng M, Chen S, Little PJ, Xu
S and Weng J: Targeting protein modifications in metabolic
diseases: Molecular mechanisms and targeted therapies. Signal
Transduct Target Ther. 8:2202023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moore LD, Le T and Fan G: DNA methylation
and its basic function. Neuropsychopharmacology. 38:23–38. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Małecki JM, Davydova E and Falnes P:
Protein methylation in mitochondria. J Biol Chem. 298:1017912022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Newman AC and Maddocks ODK: One-carbon
metabolism in cancer. Br J Cancer. 116:1499–1504. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Froese DS, Fowler B and Baumgartner MR:
Vitamin B12, folate, and the methionine remethylation
cycle-biochemistry, pathways, and regulation. J Inherit Metab Dis.
42:673–685. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Raghubeer S and Matsha TE:
Methylenetetrahydrofolate (MTHFR), the One-Carbon Cycle, and
Cardiovascular Risks. Nutrients. 13:45622021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishiyama A and Nakanishi M: Navigating
the DNA methylation landscape of cancer. Trends Genet.
37:1012–1027. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jones PA: Functions of DNA methylation:
Islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gros C, Fahy J, Halby L, Dufau I, Erdmann
A, Gregoire JM, Ausseil F, Vispé S and Arimondo PB: DNA methylation
inhibitors in cancer: Recent and future approaches. Biochimie.
94:2280–2296. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lyko F: The DNA methyltransferase family:
A versatile toolkit for epigenetic regulation. Nat Rev Genet.
19:81–92. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kulis M and Esteller M: DNA methylation
and cancer. Adv Genet. 70:27–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Delpu Y, Cordelier P, Cho WC and Torrisani
J: DNA methylation and cancer diagnosis. Int J Mol Sci.
14:15029–15058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang B, Wang JQ, Tan Y, Yuan R, Chen ZS
and Zou C: RNA methylation and cancer treatment. Pharmacol Res.
174:1059372021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bai Y, Zhao H, Liu H, Wang W, Dong H and
Zhao C: RNA methylation, homologous recombination repair and
therapeutic resistance. Biomed Pharmacother. 166:1154092023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
An Y and Duan H: The role of m6A RNA
methylation in cancer metabolism. Mol Cancer. 21:142022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen XY, Zhang J and Zhu JS: The role of
m6A RNA methylation in human cancer. Mol Cancer. 18:1032019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
He PC and He C: m6 A RNA
methylation: From mechanisms to therapeutic potential. EMBO J.
40:e1059772021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jiang X, Liu B, Nie Z, Duan L, Xiong Q,
Jin Z, Yang C and Chen Y: The role of m6A modification in the
biological functions and diseases. Signal Transduct Target Ther.
6:742021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Azzam SK, Alsafar H and Sajini AA: FTO m6A
demethylase in obesity and cancer: Implications and underlying
molecular mechanisms. Int J Mol Sci. 23:38002022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qu J, Yan H, Hou Y, Cao W, Liu Y, Zhang E,
He J and Cai Z: RNA demethylase ALKBH5 in cancer: From mechanisms
to therapeutic potential. J Hematol Oncol. 15:82022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu ZX, Li LM, Sun HL and Liu SM: Link
between m6A modification and cancers. Front Bioeng Biotechnol.
6:892018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen X, Zhou X and Wang X: m6A
binding protein YTHDF2 in cancer. Exp Hematol Oncol. 11:212022.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ramesh-Kumar D and Guil S: The IGF2BP
family of RNA binding proteins links epitranscriptomics to cancer.
Semin Cancer Biol. 86:18–31. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bi Z, Liu Y, Zhao Y, Yao Y, Wu R, Liu Q,
Wang Y and Wang X: A dynamic reversible RNA N6-methyladenosine
modification: Current status and perspectives. J Cell Physiol.
234:7948–7956. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Malbeteau L, Pham HT, Eve L, Stallcup MR,
Poulard C and Le Romancer M: How protein methylation regulates
steroid receptor function. Endocr Rev. 43:160–197. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zheng K, Chen S, Ren Z and Wang Y: Protein
arginine methylation in viral infection and antiviral immunity. Int
J Biol Sci. 19:5292–5318. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Black JC, Van Rechem C and Whetstine JR:
Histone lysine methylation dynamics: Establishment, regulation, and
biological impact. Mol Cell. 48:491–507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li Y, Chen X and Lu C: The interplay
between DNA and histone methylation: Molecular mechanisms and
disease implications. EMBO Rep. 22:e518032021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Zhang Y, Sun Z, Jia J, Du T, Zhang N, Tang
Y, Fang Y and Fang D: Overview of histone modification. Adv Exp Med
Biol. 1283:1–16. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wang H, Guo B and Guo X: Histone
demethylases in neurodevelopment and neurodegenerative diseases.
Int J Neurosci. 1–11. 2023.doi: 10.1080/00207454.2023.2276656.
View Article : Google Scholar
|
|
56
|
Harvey HA, Kimura M and Hajba A:
Toremifene: An evaluation of its safety profile. Breast.
15:142–157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Burstein HJ, Temin S, Anderson H, Buchholz
TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky
AJ, et al: Adjuvant endocrine therapy for women with hormone
receptor-positive breast cancer: American society of clinical
oncology clinical practice guideline focused update. J Clin Oncol.
32:2255–2269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Montagna E, Cancello G and Colleoni M: The
aromatase inhibitors (plus ovarian function suppression) in
premenopausal breast cancer patients: Ready for prime time? Cancer
Treat Rev. 39:886–890. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Crump M, Sawka CA, DeBoer G, Buchanan RB,
Ingle JN, Forbes J, Meakin JW, Shelley W and Pritchard KI: An
individual patient-based meta-analysis of tamoxifen versus ovarian
ablation as first line endocrine therapy for premenopausal women
with metastatic breast cancer. Breast Cancer Res Treat. 44:201–210.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Tsoutsou PG, Koukourakis MI, Azria D and
Belkacemi Y: Optimal timing for adjuvant radiation therapy in
breast cancer A comprehensive review and perspectives. Crit Rev
Oncol Hematol. 71:102–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nakhlis F, Lazarus L, Hou NJ, Acharya S,
Khan SA, Staradub VL, Rademaker AW and Morrow M: Tamoxifen use in
patients with ductal carcinoma in situ and T1a/b N0 invasive
carcinoma. J Am Coll Surg. 201:688–694. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Nichols HB, DeRoo LA, Scharf DR and
Sandler DP: Risk-Benefit profiles of women using tamoxifen for
chemoprevention. J Natl Cancer Inst. 107:3542014.PubMed/NCBI
|
|
63
|
Anderson C, Nichols HB, House M and
Sandler DP: Risk versus benefit of chemoprevention among raloxifene
and tamoxifen users with a family history of breast cancer. Cancer
Prev Res. 12:801–808. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Chlebowski RT: Current concepts in breast
cancer chemoprevention. Pol Arch Med Wewn. 124:191–199. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Nichols HB, Sturmer T, Lee VS, Anderson C,
Lee JS, Roh JM, Visvanathan K, Muss H and Kushi LH: Breast cancer
chemoprevention in an integrated health care setting. JCO Clin
Cancer Inform. 1:1–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Friedl A and Jordan VC: What do we know
and what don't we know about tamoxifen in the human uterus. Breast
Cancer Res Treat. 31:27–39. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
DeCensi A, Johansson H, Helland T, Puntoni
M, Macis D, Aristarco V, Caviglia S, Webber TB, Briata IM, D'Amico
M, et al: Association of CYP2D6 genotype and tamoxifen metabolites
with breast cancer recurrence in a low-dose trial. NPJ Breast
Cancer. 7:342021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Buijs SM, Koolen SLW, Mathijssen RHJ and
Jager A: Tamoxifen dose De-escalation: An effective strategy for
reducing adverse effects? Drugs. 84:385–401. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Reinhorn D, Yerushalmi R, Moore A,
Desnoyers A, Saleh RR, Amir E and Goldvaser H: Evolution in the
risk of adverse events of adjuvant endocrine therapy in
postmenopausal women with early-stage breast cancer. Breast Cancer
Res Treat. 182:259–266. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Wibowo E, Pollock PA, Hollis N and
Wassersug RJ: Tamoxifen in men: A review of adverse events.
Andrology. 4:776–788. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sestak I and Cuzick J: Endometrial cancer
risk in postmenopausal breast cancer patients treated with
tamoxifen or aromatase inhibitors. Expert Rev Endocrinol Metab.
11:425–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Huang B, Warner M and Gustafsson JA:
Estrogen receptors in breast carcinogenesis and endocrine therapy.
Mol Cell Endocrinol. 418:240–244. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ye H, Dudley SZ and Shaw IC: Intimate
estrogen receptor-α/ligand relationships signal biological
activity. Toxicology. 408:80–87. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ge Y, Ni X, Li J, Ye M and Jin X: Roles of
estrogen receptor α in endometrial carcinoma (Review). Oncol Lett.
26:5302023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nass N and Kalinski T: Tamoxifen
resistance: From cell culture experiments towards novel biomarkers.
Pathol Res Pract. 211:189–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Ramchand SK, Cheung YM, Yeo B and
Grossmann M: The effects of adjuvant endocrine therapy on bone
health in women with breast cancer. J Endocrinol. 241:R111–R124.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Mansouri S, Farahmand L, Hosseinzade A,
Eslami SZ and Majidzadeh AK: Estrogen can restore Tamoxifen
sensitivity in breast cancer cells amidst the complex network of
resistance. Biomed Pharmacother. 93:1320–1325. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
BachmannMoisson N, BarberiHeyob M and
Merlin JL: Molecular mechanisms of tamoxifen resistance. Bull Du
Cancer. 84:69–75. 1997.
|
|
79
|
Kulkoyluoglu E and Madak-Erdogan Z:
Nuclear and extranuclear-initiated estrogen receptor signaling
crosstalk and endocrine resistance in breast cancer. Steroids.
114:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Balfe PJ, McCann AH, Welch HM and Kerin
MJ: Estrogen receptor beta and breast cancer. Eur J Surg Oncol.
30:1043–1050. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Khalid AB and Krum SA: Estrogen receptors
alpha and beta in bone. Bone. 87:130–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hartman J, Stroem A and Gustafsson JA:
Current concepts and significance of estrogen receptor β in
prostate cancer. Steroids. 77:1262–1266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Altundag O, Altundag K and Gunduz M: DNA
methylation inhibitor, procainamide, may decrease the tamoxifen
resistance by inducing overexpression of the estrogen receptor beta
in breast cancer patients. Med Hypotheses. 63:684–687. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Levy N, Paruthiyil S, Zhao X, Vivar OI,
Saunier EF, Griffin C, Tagliaferri M, Cohen I, Speed TP and Leitman
DC: Unliganded estrogen receptor-β regulation of genes is inhibited
by tamoxifen. Mol Cell Endocrinol. 315:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tee MK, Rogatsky I, Tzagarakis-Foster C,
Cvoro A, An J, Christy RJ, Yamamoto KR and Leitman DC: Estradiol
and selective estrogen receptor modulators differentially regulate
target genes with estrogen receptors alpha and beta. Mole Biol
Cell. 15:1262–1272. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Mansouri S, Feizi N, Mahdi A, Majidzadeh
AK and Farahmand L: A review on the role of VEGF in tamoxifen
resistance. Anticancer Agents Med Chem. 18:2006–2009. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Provenzano A, Kurian S and Abraham J:
Overcoming endocrine resistance in breast cancer: Role of the PI3K
and the mTOR pathways. Expert Rev Anticancer Ther. 13:143–147.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mohite R and Doshi G: Elucidation of the
role of the epigenetic regulatory mechanisms of PI3K/Akt/mTOR
signaling pathway in human malignancies. Curr Cancer Drug Targets.
24:231–244. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Luo Q, Du R, Liu W, Huang G, Dong Z and Li
X: PI3K/Akt/mTOR signaling pathway: Role in esophageal squamous
cell carcinoma, regulatory mechanisms and opportunities for
targeted therapy. Front Oncol. 12:8523832022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Su H, Peng C and Liu Y: Regulation of
ferroptosis by PI3K/Akt signaling pathway: A promising therapeutic
axis in cancer. Front Cell Dev Biol. 12:13723302024. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Bertacchini J, Heidari N, Mediani L,
Capitani S, Shahjahani M, Ahmadzadeh A and Saki N: Targeting
PI3K/AKT/mTOR network for treatment of leukemia. Cell Mol Life Sci.
72:2337–2347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Hashemi M, Etemad S, Rezaei S, Ziaolhagh
S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, et
al: Progress in targeting PTEN/PI3K/Akt axis in glioblastoma
therapy: Revisiting molecular interactions. Biomed Pharmacother.
158:1142042023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Sadrkhanloo M, Paskeh MDA, Hashemi M,
Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS,
Salimimoghadam S, Ren J, et al: New emerging targets in
osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in
carcinogenesis. Pathol Res Pract. 251:1549022023. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Xiang Y, Yang Y, Liu J and Yang X:
Functional role of MicroRNA/PI3K/AKT axis in osteosarcoma. Front
Oncol. 13:12192112023. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Huang C, Li J and Ma TT: PI3K/Akt
signaling pathway and liver fibrosis. Zhongguo Yaolixue Tongbao.
27:1037–1041. 2011.
|
|
96
|
Li L, Han C and Liu X: Regulation of
PI3K-Akt-mTORC1 signal pathway in the cell growth and
proliferation. J Biology. 31:75–77. 2014.
|
|
97
|
Minami A, Nakanishi A, Ogura Y, Kitagishi
Y and Matsuda S: Connection between tumor suppressor BRCA1 and PTEN
in damaged DNA repair. Front Oncol. 4:318. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Zhou J, Chen Q, Zou Y, Chen H, Qi L and
Chen Y: Stem cells and cellular origins of breast cancer: Updates
in the rationale, controversies, and therapeutic implications.
Front Oncol. 9:8202019. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zheng Q, Zhang M, Zhou F, Zhang L and Meng
X: The breast cancer stem cells traits and drug resistance. Front
Pharmacol. 11:5999652021. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Telang N: Stem cell models for cancer
therapy. Int J Mol Sci. 23:70552022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Haiduk TS, Sicking M, Brücksken KA,
Espinoza-Sánchez NA, Eder KM, Kemper B, Eich HT, Götte M, Greve B
and Troschel FM: Dysregulated stem cell markers Musashi-1 and
Musashi-2 are associated with therapy resistance in inflammatory
breast cancer. Arch Med Res. 54:1028552023. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Gelsomino L, Panza S, Giordano C, Barone
I, Gu G, Spina E, Catalano S, Fuqua S and Andò S: Mutations in the
estrogen receptor alpha hormone binding domain promote stem cell
phenotype through notch activation in breast cancer cell lines.
Cancer Lett. 428:12–20. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Ghasemi F, Sarabi PZ, Athari SS and
Esmaeilzadeh A: Therapeutics strategies against cancer stem cell in
breast ca ncer. Int J Biochem Cell Biol. 109:76–81. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Albain KS, Czerlanis C, Zlobin A,
Covington KR, Rajan P, Godellas C, Bova D, Lo SS, Robinson P,
Sarker S, et al: S1-5: Modulation of cancer and stem cell
biomarkers by the notch inhibitor MK-0752 added to endocrine
therapy for early stage ER + breast cancer. Cancer Res. 71 (Suppl
24):S1–S5. 2011. View Article : Google Scholar
|
|
105
|
Schott AF, Landis MD, Dontu G, Griffith
KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT,
et al: Preclinical and clinical studies of gamma secretase
inhibitors with docetaxel on human breast tumors. Clin Cancer Res.
19:1512–1524. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Wang D, Xu J, Liu B, He X, Zhou L, Hu X,
Qiao F, Zhang A, Xu X, Zhang H, et al: IL6 blockade potentiates the
anti-tumor effects of γ-secretase inhibitors in Notch3-expressing
breast cancer. Cell Death Differ. 25:330–339. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Means-Powell JA, Mayer IA, Ismail-Khan R,
Del Valle L, Tonetti D, Abramson VG, Sanders MS, Lush RM,
Sorrentino C, Majumder S and Miele L: A Phase ib dose escalation
trial of RO4929097 (a γ-secretase inhibitor) in combination with
exemestane in patients with er plus metastatic breast cancer (MBC).
Clin Breast Cancer. 22:103–114. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Jeselsohn R, Cornwell M, Pun M, Buchwalter
G, Nguyen M, Bango C, Huang Y, Kuang Y, Paweletz C, Fu X, et al:
Embryonic transcription factor SOX9 drives breast cancer endocrine
resistance. Proc Natl Acad Sci USA. 114:E4482–E4491. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Poulard C, Pham TH, Drouet Y, Jacquemetton
J, Surmielova A, Kassem L, Mery B, Lasset C, Reboulet J, Treilleux
I, et al: Nuclear PRMT5 is a biomarker of sensitivity to tamoxifen
in ERα+ breast cancer. Embo Mol Med. 15:e172482023. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Zhou J, Xu M, Le K, Ming J, Guo H, Ruan S
and Huang T: SRC promotes tamoxifen resistance in breast cancer via
Up-Regulating SIRT1. Onco Targets Ther. 13:4635–4647. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Jogi A, Ehinger A, Hartman L and Alkner S:
Expression of HIF-1α is related to a poor prognosis and tamoxifen
resistance in contralateral breast cancer. PLoS One.
14:e02261502019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ward A, Balwierz A, Zhang JD, Küblbeck M,
Pawitan Y, Hielscher T, Wiemann S and Sahin Ö: Re-expression of
microRNA-375 reverses both tamoxifen resistance and accompanying
EMT-like properties in breast cancer. Oncogene. 32:1173–1182. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Cittelly DM, Das PM, Spoelstra NS,
Edgerton SM, Richer JK, Thor AD and Jones FE: Downregulation of
miR-342 is associated with tamoxifen resistant breast tumors. Mol
Cancer. 9:3172010. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Xu E, Hu M, Ge R, Tong D, Fan Y, Ren X and
Liu Y: LncRNA-42060 regulates tamoxifen sensitivity and tumor
development via regulating the miR-204-5p/SOX4 axis in canine
mammary gland tumor cells. Front Vet Sci. 8:6546942021. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Sukocheva OA, Lukina E, Friedemann M,
Menschikowski M, Hagelgans A and Aliev G: The crucial role of
epigenetic regulation in breast cancer anti-estrogen resistance:
Current findings and future perspectives. Semin Cancer Biol.
82:35–59. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Kim SS, Lee MH and Lee MO: Histone
methyltransferases regulate the transcriptional expression of ERα
and the proliferation of tamoxifen-resistant breast cancer cells.
Breast Cancer Res Treat. 180:45–54. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zhang J, Zhou C, Jiang H, Liang L, Shi W,
Zhang Q, Sun P, Xiang R, Wang Y and Yang S: ZEB1 induces ER-α
promoter hypermethylation and confers antiestrogen resistance in
breast cancer. Cell Death Dis. 8:e27322017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Jiménez-Garduño AM, Mendoza-Rodríguez MG,
Urrutia-Cabrera D, Domínguez-Robles MC, Pérez-Yépez EA,
Ayala-Sumuano JT and Meza I: IL-1β induced methylation of the
estrogen receptor ERα gene correlates with EMT and chemoresistance
in breast cancer cells. Biochem Biophys Res Commun. 490:780–785.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Kim MR, Wu MJ, Zhang Y, Yang JY and Chang
CJ: TET2 directs mammary luminal cell differentiation and endocrine
response. Nat Commun. 11:46422020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chang HG, Kim SJ, Chung KW, Noh DY, Kwon
Y, Lee ES and Kang HS: Tamoxifen-resistant breast cancers show less
frequent methylation of the estrogen receptor beta but not the
estrogen receptor alpha gene. J Mol Med (Berl). 83:132–139. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zou JX, Duan Z, Wang J, Sokolov A, Xu J,
Chen CZ, Li JJ and Chen HW: Kinesin family deregulation coordinated
by bromodomain protein ANCCA and histone methyltransferase MLL for
breast cancer cell growth, survival, and tamoxifen resistance. Mol
Cancer Res. 12:539–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Jin ML, Kim YW, Jin HL, Kang H, Lee EK,
Stallcup MR and Jeong KW: Aberrant expression of SETD1A promotes
survival and migration of estrogen receptor α-positive breast
cancer cells. Int J Cancer. 143:2871–2883. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Stone A, Zotenko E, Locke WJ, Korbie D,
Millar EK, Pidsley R, Stirzaker C, Graham P, Trau M, Musgrove EA,
et al: DNA methylation of oestrogen-regulated enhancers defines
endocrine sensitivity in breast cancer. Nat Commun. 6:77582015.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Gautam N, Verma H, Choudhary S, Kaur S and
Silakari O: Functional relationship of SNP (Ala490Thr) of an
epigenetic gene EZH2 results in the progression and poor survival
of ER+/tamoxifen treated breast cancer patients. J Genet.
100:862021. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wu Y, Zhang Z, Cenciarini ME, Proietti CJ,
Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, et al:
Tamoxifen resistance in breast cancer is regulated by the
EZH2-ERα-GREB1 transcriptional axis. Cancer Res. 78:671–684. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Li J, Liang Y, Zhou S, Chen J and Wu C:
UCHL1 contributes to insensitivity to endocrine therapy in
triple-negative breast cancer by deubiquitinating and stabilizing
KLF5. Breast Cancer Res. 26:442024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Redeuilh G, Attia A, Mester J and Sabbah
M: Transcriptional activation by the oestrogen receptor α is
modulated through inhibition of cyclin-dependent kinases. Oncogene.
21:5773–5782. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wang L, Zhang X and Wang ZY: The Wilms'
tumor suppressor WT1 regulates expression of members of the
epidermal growth factor receptor (EGFR) and estrogen receptor in
acquired tamoxifen resistance. Anticancer Res. 30:3637–3642.
2010.PubMed/NCBI
|
|
129
|
Best SA, Hutt KJ, Fu NY, Vaillant F, Liew
SH, Hartley L, Scott CL, Lindeman GJ and Visvader JE: Dual roles
for Id4 in the regulation of estrogen signaling in the mammary
gland and ovary. Development. 141:3159–3164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Mobini K, Tamaddon G, Fardid R, Keshavarzi
M and Mohammadi-Bardbori A: Aryl hydrocarbon-estrogen alpha
receptor-dependent expression of miR-206, miR-27b, and miR-133a
suppress cell proliferation and migration in MCF-7 cells. J Biochem
Mol Toxicol. 33:e223042019. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Li Z, Yu D, Li H, Lv Y and Li S: Long
non-coding RNA UCA1 confers tamoxifen resistance in breast cancer
endocrinotherapy through regulation of the EZH2/p21 axis and the
PI3K/AKT signaling pathway. Int J Oncol. 54:1033–1042.
2019.PubMed/NCBI
|
|
132
|
Ren C, Tang X and Lan H: Comprehensive
analysis based on DNA methylation and RNA-seq reveals
hypermethylation of the up-regulated WT1 gene with potential
mechanisms in PAM50 subtypes of breast cancer. PeerJ. 9:e113772021.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Zhang Y, Zhang B, Fang J and Cao X:
Hypomethylation of DNA-binding inhibitor 4 serves as a potential
biomarker in distinguishing acquired tamoxifen-refractory breast
cancer. Int J Clin Exp Pathol. 8:9500–9505. 2015.PubMed/NCBI
|
|
134
|
Li X, Wu Y, Liu A and Tang X: MiR-27b is
epigenetically downregulated in tamoxifen resistant breast cancer
cells due to promoter methylation and regulates tamoxifen
sensitivity by targeting HMGB3. Biochem Biophys Res Commun.
477:768–773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhang X, Carlisle SM, Doll MA, Martin RCG,
States JC, Klinge CM and Hein DW: High N-Acetyltransferase 1
expression is associated with estrogen receptor expression in
breast tumors, but is not Under Direct Regulation by Estradiol,
5α-androstane-3β, 17β-Diol, or dihydrotestosterone in breast cancer
cells. J Pharmacol Exp Ther. 365:84–93. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
González-Bengtsson A, Asadi A, Gao H,
Dahlman-Wright K and Jacobsson A: Estrogen enhances the expression
of the polyunsaturated fatty acid elongase Elovl2 via ERα in breast
cancer cells. PLoS One. 11:e01642412016. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Rickard DJ, Waters KM, Ruesink TJ, Khosla
S, Katzenellenbogen JA, Katzenellenbogen BS, Riggs BL and Spelsberg
TC: Estrogen receptor isoform-specific induction of progesterone
receptors in human osteoblasts. J Bone Miner Res. 17:580–592. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Kim SJ, Kang HS, Jung SY, Min SY, Lee S,
Kim SW, Kwon Y, Lee KS, Shin KH and Ro J: Methylation patterns of
genes coding for drug-metabolizing enzymes in tamoxifen-resistant
breast cancer tissues. J Mol Med (Berl). 88:1123–1131. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Sun H, Wang G, Cai J, Wei X, Zeng Y, Peng
Y and Zhuang J: Long non-coding RNA H19 mediates
N-acetyltransferase 1 gene methylation in the development of
tamoxifen resistance in breast cancer. Exp Ther Med. 23:122022.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Kim HW, Baek M, Jung S, Jang S, Lee H,
Yang SH, Kwak BS and Kim SJ: ELOVL2-AS1 suppresses tamoxifen
resistance by sponging miR-1233-3p in breast cancer. Epigenetics.
18:22763842023. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Pathiraja TN, Shetty PB, Jelinek J, He R,
Hartmaier R, Margossian AL, Hilsenbeck SG, Issa JP and Oesterreich
S: Progesterone receptor isoform-specific promoter methylation:
Association of PRA promoter methylation with worse outcome in
breast cancer patients. Clin Cancer Res. 17:4177–4186. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Chen H, Li L, Liu H, Qin P, Chen R, Liu S,
Xiong H, Li Y, Yang Z, Xie M, et al: PAX2 is regulated by
estrogen/progesterone through promoter methylation in endometrioid
adenocarcinoma and has an important role in carcinogenesis via the
AKT/mTOR signaling pathway. J Pathol. 262:467–479. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Oesterreich S, Deng W, Jiang S, Cui X,
Ivanova M, Schiff R, Kang K, Hadsell DL, Behrens J and Lee AV:
Estrogen-mediated down-regulation of E-cadherin in breast cancer
cells. Cancer Res. 63:5203–5208. 2003.PubMed/NCBI
|
|
144
|
Jahangiri R, Mosaffa F, Emami Razavi A,
Teimoori-Toolabi L and Jamialahmadi K: PAX2 promoter methylation
and AIB1 overexpression promote tamoxifen resistance in breast
carcinoma patients. J Oncol Pharm Pract. 28:310–325. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wang Q, Gun M and Hong XY: Induced
tamoxifen resistance is mediated by increased methylation of
E-Cadherin in estrogen receptor-expressing breast cancer cells. Sci
Rep. 9:141402019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Kim HW, Park JE, Baek M, Kim H, Ji HW, Yun
SH, Jeong D, Ham J, Park S, Lu X, et al: Matrix Metalloproteinase-1
(MMP1) upregulation through promoter hypomethylation enhances
tamoxifen resistance in breast cancer. Cancers (Basel).
14:12322022. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Jung HH, Park YH, Jun HJ, Kong J, Kim JH,
Kim JA, Yun J, Sun JM, Won YW, Lee S, et al: Matrix
Metalloproteinase-1 expression can be upregulated through
mitogen-activated protein kinase pathway under the influence of
human epidermal growth factor Receptor 2 synergized with estrogen
receptor. Mol Cancer Res. 8:1037–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Ren W, Yi H, Bao Y, Liu Y and Gao X:
Oestrogen inhibits PTPRO to prevent the apoptosis of renal
podocytes. Exp Ther Med. 17:2373–2380. 2019.PubMed/NCBI
|
|
149
|
Ramaswamy B, Majumder S, Roy S, Ghoshal K,
Kutay H, Datta J, Younes M, Shapiro CL, Motiwala T and Jacob ST:
Estrogen-mediated suppression of the gene encoding protein tyrosine
phosphatase PTPRO in human breast cancer: Mechanism and role in
tamoxifen sensitivity. Mol Endocrinol. 23:176–187. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Fan Y, Xie G, Wang Z, Wang Y, Wang Y,
Zheng H and Zhong X: PTEN promoter methylation predicts 10-year
prognosis in hormone receptor-positive early breast cancer patients
who received adjuvant tamoxifen endocrine therapy. Breast Cancer
Res Treat. 192:33–42. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH,
Lee KY, Ahn SG, Yoon JH and Kang KW: Role of PTEN promoter
methylation in tamoxifen-resistant breast cancer cells. Breast
Cancer Res Treat. 130:73–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Phuong NT, Kim SK, Im JH, Yang JW, Choi
MC, Lim SC, Lee KY, Kim YM, Yoon JH and Kang KW: Induction of
methionine adenosyltransferase 2A in tamoxifen-resistant breast
cancer cells. Oncotarget. 7:13902–13916. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Liu Z, Liu J, Ebrahimi B, Pratap UP, He Y,
Altwegg KA, Tang W, Li X, Lai Z, Chen Y, et al: SETDB1 interactions
with PELP1 contributes to breast cancer endocrine therapy
resistance. Breast Cancer Res. 24:262022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Schomann T, Mirzakhani K, Kallenbach J, Lu
J, Rasa SMM, Neri F and Baniahmad A: Androgen-Induced MIG6
regulates phosphorylation of retinoblastoma protein and AKT to
counteract Non-Genomic AR signaling in prostate cancer cells.
Biomolecules. 12:10482022. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Wang Q, Li J, Wu W, Shen R, Jiang H, Qian
Y, Tang Y, Bai T, Wu S, Wei L, et al: Smad4-dependent suppressor
pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt
pathway in pancreatic cancer. Oncotarget. 7:11208–11222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Yue C, Bai Y, Piao Y and Liu H: DOK7
inhibits cell proliferation, migration, and invasion of breast
cancer via the PI3K/PTEN/AKT pathway. J Oncol. 2021:40352572021.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Barkovskaya A, Seip K, Prasmickaite L,
Mills IG, Moestue SA and Itkonen HM: Inhibition of O-GlcNAc
transferase activates tumor-suppressor gene expression in
tamoxifen-resistant breast cancer cells. Sci Rep. 10:169922020.
View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Maier S, Nimmrich I, Koenig T,
Eppenberger-Castori S, Bohlmann I, Paradiso A, Spyratos F, Thomssen
C, Mueller V, Nährig J, et al: DNA-methylation of the homeodomain
transcription factor PITX2 reliably predicts risk of distant
disease recurrence in tamoxifen-treated, node-negative breast
cancer patients-Technical and clinical validation in a multi-centre
setting in collaboration with the European Organisation for
Research and Treatment of Cancer (EORTC) PathoBiology group. Eur J
Cancer. 43:1679–1686. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Gowdini E, Aleyasin SA, Ramezani N, Nafisi
N and Tutuni M: DOK7 CpG hypermethylation in blood leukocytes as an
epigenetic biomarker for acquired tamoxifen resistant in breast
cancer. J Hum Genet. 68:33–38. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Wujak M, Veith C, Wu CY, Wilke T, Kanbagli
ZI, Novoyatleva T, Guenther A, Seeger W, Grimminger F, Sommer N, et
al: Adenylate Kinase 4-A key regulator of proliferation and
metabolic shift in human pulmonary arterial smooth muscle cells via
Akt and HIF-1α signaling pathways. Int J Mol Sci. 22:103712021.
View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Liu X, Gonzalez G, Dai X, Miao W, Yuan J,
Huang M, Bade D, Li L, Sun Y and Wang Y: Adenylate Kinase 4
modulates the resistance of breast cancer cells to tamoxifen
through an m6A-Based epitranscriptomic mechanism. Mol Ther.
28:2593–2604. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Ye L, Lin C, Wang X, Li Q, Li Y, Wang M,
Zhao Z, Wu X, Shi D, Xiao Y, et al: Epigenetic silencing of SALL2
confers tamoxifen resistance in breast cancer. EMBO Mol Med.
11:e106382019. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Huang J, Li J, Tang J, Wu Y, Dai F, Yi Z,
Wang Y, Li Y, Wu Y, Ren G and Xiang T: ZDHHC22-mediated mTOR
palmitoylation restrains breast cancer growth and endocrine therapy
resistance. Int J Biol Sci. 18:2833–2850. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Al-Ansari MM, Hendrayani SF, Tulbah A,
Al-Tweigeri T, Shehata AI and Aboussekhra A: p16INK4A represses
breast stromal fibroblasts migration/invasion and their
VEGF-A-dependent promotion of angiogenesis through Akt inhibition.
Neoplasia. 14:1269–1277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Zhou J and Chen C: Suppression of
malignant melanoma by knocking down growth differentiation
factor-15 via inhibiting PTEN/PI3K/AKT signaling pathway. J Cancer.
15:1115–1123. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Chen S, Yao F, Xiao Q, Liu Q, Yang Y, Li
X, Jiang G, Kuno T and Fang Y: EZH2 inhibition sensitizes
tamoxifen-resistant breast cancer cells through cell cycle
regulation. Mol Med Rep. 17:2642–2650. 2018.PubMed/NCBI
|
|
167
|
Stone A, Valdés-Mora F, Gee JM, Farrow L,
McClelland RA, Fiegl H, Dutkowski C, McCloy RA, Sutherland RL,
Musgrove EA and Nicholson RI: Tamoxifen-induced epigenetic
silencing of oestrogen-regulated genes in anti-hormone resistant
breast cancer. PLoS One. 7:e404662012. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zhao W, Sun M, Li S, Chen Z and Geng D:
Transcription factor ATF3 mediates the radioresistance of breast
cancer. J Cell Mol Med. 22:4664–4675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Liu X, Yuan J, Zhang X, Li L, Dai X, Chen
Q and Wang Y: ATF3 modulates the resistance of breast cancer cells
to tamoxifen through an N6-Methyladenosine-Based epitranscriptomic
mechanism. Chem Res Toxicol. 34:1814–1821. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Lv Y, Fang L, Ding P and Liu R:
PI3K/Akt-Beclin1 signaling pathway positively regulates
phagocytosis and negatively mediates NF-κB-dependent inflammation
in Staphylococcus aureus-infected macrophages. Biochem Biophys Res
Commun. 510:284–289. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Wang J, Xie S, Yang J, Xiong H, Jia Y,
Zhou Y, Chen Y, Ying X, Chen C, Ye C, et al: The long noncoding RNA
H19 promotes tamoxifen resistance in breast cancer via autophagy. J
Hematol Oncol. 12:812019. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Gu Q-Z, Nijiati A, Gao X, Tao KL, Li CD,
Fan XP and Tian Z: TROP2 promotes cell proliferation and migration
in osteosarcoma through PI3K/AKT signaling. Mol Med Rep.
8:1782–1788. 2018.PubMed/NCBI
|
|
173
|
Zimmers SM, Browne EP, Williams KE, Jawale
RM, Otis CN, Schneider SS and Arcaro KF: TROP2 methylation and
expression in tamoxifen-resistant breast cancer. Cancer Cell Int.
18:942018. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Zhai J, Jiang JF and Shi L: Lycorine
weakens tamoxifen resistance of breast cancer via abrogating
HAGLR-mediated epigenetic suppression on VGLL4 by DNMT1. Kaohsiung
J Med Sci. 39:278–289. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Watanabe T, Oba T, Tanimoto K, Shibata T,
Kamijo S and Ito KI: Tamoxifen resistance alters sensitivity to
5-fluorouracil in a subset of estrogen receptor-positive breast
cancer. PLoS One. 16:e02528222021. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Williams KE, Anderton DL, Lee MP,
Pentecost BT and Arcaro KF: High-density array analysis of DNA
methylation in Tamoxifen-resistant breast cancer cell lines.
Epigenetics. 9:297–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Ansar M, Thu LTA, Hung CS, Su CM, Huang
MH, Liao LM, Chung YM and Lin RK: Promoter hypomethylation and
overexpression of TSTD1 mediate poor treatment response in breast
cancer. Front Oncol. 12:10042612022. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Pietkiewicz PP, Lutkowska A, Lianeri M and
Jagodzinski PP: Tamoxifen epigenetically modulates CXCL12
expression in MCF-7 breast cancer cells. Biomed Pharmacother.
64:54–57. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Martens JW, Nimmrich I, Koenig T, Look MP,
Harbeck N, Model F, Kluth A, Bolt-de Vries J, Sieuwerts AM,
Portengen H, et al: Association of DNA methylation of phosphoserine
aminotransferase with response to endocrine therapy in patients
with recurrent breast cancer. Cancer Res. 65:4101–4117. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Wang B, Li D, Rodriguez-Juarez R, Farfus
A, Storozynsky Q, Malach M, Carpenter E, Filkowski J, Lykkesfeldt
AE and Kovalchuk O: A suppressive role of guanine
nucleotide-binding protein subunit beta-4 inhibited by DNA
methylation in the growth of anti-estrogen resistant breast cancer
cells. BMC cancer. 18:8172018. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Kedia-Mokashi NA, Kadam L, Ankolkar M,
Dumasia K and Balasinor NH: Aberrant methylation of multiple
imprinted genes in embryos of tamoxifen-treated male rats.
Reproduction. 146:155–168. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Liggett TE, Melnikov AA, Marks JR and
Levenson VV: Methylation patterns in cell-free plasma DNA reflect
removal of the primary tumor and drug treatment of breast cancer
patients. Int J Cancer. 128:492–499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Pathak S, Kedia-Mokashi N, Saxena M,
D'Souza R, Maitra A, Parte P, Gill-Sharma M and Balasinor N: Effect
of tamoxifen treatment on global and insulin-like growth factor
2-H19 locus-specific DNA methylation in rat spermatozoa and its
association with embryo loss. Fertil Steril. 91:2253–2263. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Ge Y, Zhan Z, Ye M and Jin X: The
crosstalk between ubiquitination and endocrine therapy. J Mol Med
(Berl). 101:461–486. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Kubarek Ł and Jagodzinski PP: Epigenetic
up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol
and tamoxifen is associated with formation of DNA methyltransferase
3B4 splice variant in Ishikawa endometrial adenocarcinoma cells.
FEBS Lett. 581:1441–1448. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Wu H, Chen Y, Liang J, Shi B, Wu G, Zhang
Y, Wang D, Li R, Yi X, Zhang H, et al: Hypomethylation-linked
activation of PAX2 mediates tamoxifen-stimulated endometrial
carcinogenesis. Nature. 438:981–987. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Tryndyak VP, Muskhelishvili L, Kovalchuk
O, Rodriguez-Juarez R, Montgomery B, Churchwell MI, Ross SA, Beland
FA and Pogribny IP: Effect of long-term tamoxifen exposure on
genotoxic and epigenetic changes in rat liver: Implications for
tamoxifen-induced hepatocarcinogenesis. Carcinogenesis.
27:1713–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Fan M, Yan PS, Hartman-Frey C, Chen L,
Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, et al:
Diverse gene expression and DNA methylation profiles correlate with
differential adaptation of breast cancer cells to the antiestrogens
tamoxifen and fulvestrant. Cancer Res. 66:11954–11966. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Snider H, Villavarajan B, Peng Y, Shepherd
LE, Robinson AC and Mueller CR: Region-specific glucocorticoid
receptor promoter methylation has both positive and negative
prognostic value in patients with estrogen receptor-positive breast
cancer. Clin Epigenetics. 11:1552019. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Kala R and Tollefsbol TO: A novel
combinatorial epigenetic therapy using resveratrol and
pterostilbene for restoring estrogen Receptor-α (ERα) expression in
ERα-Negative breast cancer cells. PLoS One. 11:e01550572016.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Zhang WJ, Xu DF, Fan QX, Wu XA, Wang F,
Wang R and Wang LX: Arsenic trioxide restores ERα expression in
ERα-negative human breast cancer cells and its treatment efficacy
in combination with tamoxifen in xenografts in nude mice. Zhonghua
Zhong Liu Za Zhi. 34:645–651. 2012.(In Chinese). PubMed/NCBI
|
|
192
|
Tang B, Peng ZH and Jiang J: The
synergistic inhibitory effect of 5-aza-2-deoxycytidine and
Tamoxifen on estrogen receptor alpha negative breast cancer cell
lines in vitro. Zhonghua Wai Ke Za Zhi. 43:1545–1549. 2005.(In
Chinese). PubMed/NCBI
|
|
193
|
Selmin OI, Donovan MG, Skovan B,
Paine-Murieta GD and Romagnolo DF: Arsenic-induced BRCA1 CpG
promoter methylation is associated with the downregulation of ERα
and resistance to tamoxifen in MCF7 breast cancer cells and mouse
mammary tumor xenografts. Int J Oncol. 54:869–878. 2019.PubMed/NCBI
|
|
194
|
Wu HT, Liu YE, Hsu KW, Wang YF, Chan YC,
Chen Y and Chen DR: MLL3 induced by luteolin causes apoptosis in
Tamoxifen-Resistant breast cancer cells through H3K4
monomethylation and suppression of the PI3K/AKT/mTOR Pathway. Am J
Chin Med. 48:1221–1241. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Jin K, Lan H, Zhang J, Lv J, Chen Y, Yu K
and Wang W: UBASH3B promotes tamoxifen resistance and could be
negatively regulated by ESR1. Oncotarget. 9:8326–8333. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Jayasree PJ, Dutta S, Karemore P and
Khandelia P: Crosstalk between m6A RNA methylation and miRNA
biogenesis in cancer: An unholy nexus. Mol Biotechnol. Oct
13–2023.doi: 10.1007/s12033-023-00921-w. View Article : Google Scholar
|
|
197
|
Noh EM, Lee YR, Chay KO, Chung EY, Jung
SH, Kim JS and Youn HJ: Estrogen receptor α induces down-regulation
of PTEN through PI3-kinase activation in breast cancer cells. Mol
Med Rep. 4:215–219. 2011.PubMed/NCBI
|
|
198
|
Khatpe AS, Adebayo AK, Herodotou CA, Kumar
B and Nakshatri H: Nexus between PI3K/AKT and estrogen receptor
signaling in breast cancer. Cancers (Basel). 13:3692021. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Zhu D, Zeng S, Su C, Li J, Xuan Y, Lin Y,
Xu E and Fan Q: The interaction between DNA methylation and tumor
immune microenvironment: From the laboratory to clinical
applications. Clin Epigenetics. 16:242024. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Sina AA, Carrascosa LG and Trau M: DNA
Methylation-based point-of-care cancer detection: Challenges and
possibilities. Trends Mol Med. 25:955–966. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Wang B, Wang M, Lin Y, Zhao J, Gu H and Li
X: Circulating tumor DNA methylation: A promising clinical tool for
cancer diagnosis and management. Clin Chem Lab Med. Mar 7–2024.doi:
10.1515/cclm-2023-1327. View Article : Google Scholar
|
|
202
|
Garcia-Ortiz MV, Cano-Ramirez P,
Toledano-Fonseca M, Aranda E and Rodriguez-Ariza A: Diagnosing and
monitoring pancreatic cancer through cell-free DNA methylation:
Progress and prospects. Biomark Res. 11:882023. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Fan S and Chi W: Methods for genome-wide
DNA methylation analysis in human cancer. Brief Funct Genomics.
15:432–442. 2016.PubMed/NCBI
|
|
204
|
Liu B, Wang T, Wang H, Zhang L, Xu F, Fang
R, Li L, Cai X, Wu Y, Zhang W and Ye L: Oncoprotein HBXIP enhances
HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen
resistance in breast cancer. J Hematol Oncol. 11:262018. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Geter PA, Ernlund AW, Bakogianni S, Alard
A, Arju R, Giashuddin S, Gadi A, Bromberg J and Schneider RJ:
Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen
resistance and estrogen independence through selective mRNA
translation reprogramming. Genes Dev. 31:2235–2249. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Filipčík P, Curry JR and Mace PD: When
Worlds Collide-mechanisms at the interface between phosphorylation
and ubiquitination. J Mol Biol. 429:1097–1113. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Bailey LT, Northall SJ and Schalch T:
Breakers and amplifiers in chromatin circuitry: Acetylation and
ubiquitination control the heterochromatin machinery. Curr Opin
Struct Biol. 71:156–163. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Shukla A, Chaurasia P and Bhaumik SR:
Histone methylation and ubiquitination with their cross-talk and
roles in gene expression and stability. Cell Mol Life Sci.
66:1419–1433. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Separovich RJ, Pang CNI and Wilkins MR:
Controlling the controllers: Regulation of histone methylation by
phosphosignalling. Trends Biochem Sci. 45:1035–1048. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Blackburn SA, Parks RM and Cheung KL:
Fulvestrant for the treatment of advanced breast cancer. Expert Rev
Anticancer Ther. 18:619–628. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Intabli H, Gee JM, Oesterreich S, Yeoman
MS, Allen MC, Qattan A and Flint MS: Glucocorticoid induced loss of
oestrogen receptor alpha gene methylation and restoration of
sensitivity to fulvestrant in triple negative breast cancer. Gene.
851:1470222023. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Hopcroft L, Wigmore EM, Williamson SC, Ros
S, Eberlein C, Moss JI, Urosevic J, Carnevalli LS, Talbot S,
Bradshaw L, et al: Combining the AKT inhibitor capivasertib and
SERD fulvestrant is effective in palbociclib-resistant ER+ breast
cancer preclinical models. NPJ Breast Cancer. 9:642023. View Article : Google Scholar : PubMed/NCBI
|
